Laurus Labs has reported results for fourth quarter and year ended March 31, 2019.
The company has reported a fall of 5.18% in its net profit at Rs 43.95 crore for the quarter under review as compared to Rs 46.35 crore for the same quarter in the previous year. However, total income of the company increased by 12.28% at Rs 619.26 crore for Q4FY19 as compared Rs 551.55 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 4.21% in its net profit at Rs 43.18 crore for the quarter under review as compared to Rs 45.08 crore for the same quarter in the previous year. However, total income of the company increased by 12.64% at Rs 636.78 crore for Q4FY19 as compared Rs 565.32 crore for the corresponding quarter previous year.
For the year ended March 31, 2019, the company has reported a fall of 45.14% in its net profit at Rs 94.99 crore as compared to Rs 173.14 crore for the previous year. However, total income of the company increased by 8.90% at Rs 2,252.27 crore for year under review as compared to Rs 2,068.12 crore for year ended March 31, 2018.
For the year ended March 31, 2019, on the consolidated basis, the company has reported a fall of 44.06% in its net profit at Rs 93.76 crore as compared to Rs 167.61 crore for the previous year. However, total income of the company increased by 10% at Rs 2,308.07 crore for year under review as compared to Rs 2,098.20 crore for year ended March 31, 2018.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1748.60 |
Dr. Reddys Lab | 1164.70 |
Cipla | 1508.70 |
Lupin | 2035.30 |
Zydus Lifesciences | 903.10 |
View more.. |